ir.chimerix.com
Investor Overview - Chimerix, Inc.The Investor Relations website contains information about Chimerix, Inc. business for stockholders, potential investors, and financial analysts.
http://ir.chimerix.com/
The Investor Relations website contains information about Chimerix, Inc. business for stockholders, potential investors, and financial analysts.
http://ir.chimerix.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
2 seconds
PAGES IN
THIS WEBSITE
21
SSL
EXTERNAL LINKS
33
SITE IP
206.200.251.19
LOAD TIME
1.998 sec
SCORE
6.2
Investor Overview - Chimerix, Inc. | ir.chimerix.com Reviews
https://ir.chimerix.com
The Investor Relations website contains information about Chimerix, Inc. business for stockholders, potential investors, and financial analysts.
ir.chimerix.com
Historic Stock Lookup - Chimerix, Inc.
http://ir.chimerix.com/stocklookup.cfm
Adjusted historic prices for the week of October 31, 2016. Oct 31, 2016. Nov 1, 2016. Nov 2, 2016. Nov 3, 2016. Year End Stock Prices. The historical stock information provided is for informational purposes only and is not intended for trading purposes. The historical stock information is provided by Mergent, a third party service, and Chimerix, Inc. does not maintain or provide information directly to this service. Prices display split-adjusted cost basis per share on that date.
SEC Filings - Chimerix, Inc.
http://ir.chimerix.com/sec.cfm
Annual Reports and Proxies. All (excl. Section 16). Sep 19, 2016. Trost, timothy w. File is in Briefcase. Sep 19, 2016. File is in Briefcase. Sep 19, 2016. Berrey, m michelle. File is in Briefcase. Sep 16, 2016. Leonard, john m. File is in Briefcase. Aug 31, 2016. Berrey, m michelle. File is in Briefcase. Aug 19, 2016. File is in Briefcase. Aug 8, 2016. File is in Briefcase. Aug 8, 2016. File is in Briefcase. Jul 18, 2016. File is in Briefcase. Jun 28, 2016. Daly, james m. File is in Briefcase.
Investor Relations - Chimerix, Inc.
http://ir.chimerix.com/index.cfm
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerixs proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. Nov 4, 2016. Delayed at least 20 minutes. Oct 31, 2016. Oct 27, 2016. Sep 6, 2016. Aug 8, 2016. Nov 7, 2016. Sep 16, 2...
Press Releases - Chimerix, Inc.
http://ir.chimerix.com/releases.cfm
Aug 8, 2016. Chimerix Announces Second Quarter 2016 Financial Results. European Commission Granted Orphan Drug Designation for Brincidofovir for the Treatment of Adenovirus - - Conference Call at 8:30 am ET Today - DURHAM, N.C., Aug. 08, 2016 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results a. File is in Briefcase. Aug 1, 2016. File is in Briefcase. Jun 7, 2016. DURHAM, N.C., June 07...Maint...
Chimerix to Present at UBS Global Healthcare Conference (NASDAQ:CMRX)
http://ir.chimerix.com/releasedetail.cfm?ReleaseID=912530
May 12, 2015. File is in Briefcase. Chimerix to Present at UBS Global Healthcare Conference. DURHAM, N.C. May 12, 2015. Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that. MD, MS, Chief Medical Officer of. Will present at the. UBS Global Healthcare Conference. Tuesday, May 19, 2015. Sheraton New York Times Square Hotel. Where it will be archived for 90 days. Is working with BARDA to develop brincidofovir as a potential med...
TOTAL PAGES IN THIS WEBSITE
21
Chimerix | Antiviral Drugs for DNA Viruses | Clinical Trials
http://www.chimerix.com/discovery-clinical-trials/brincidofovir/brincidofovir-suppress-trial
Research & Development. Financials & Fillings. Our proprietary technology has given rise to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid conjugate that has demonstrated antiviral activity and safety in an orally administered dosing regimen. Brincidofovir has shown in vitro. Activity against all five families of DNA viruses that affect humans, including cytomegalovirus (CMV), adenovirus, BK virus and herpes simplex viruses. The AdVise (NCT02087306) trial is a fully enrolled, open-label...
Chimerix | Antiviral Drugs for DNA Viruses | News
http://www.chimerix.com/news-and-publications/press-releases
Research & Development. Financials & Fillings. Chimerix Announces Second Quarter 2016 Financial Results. Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016. Chimerix to Participate in Panel on North Carolina’s Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium. Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results. Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016. Terms & Conditions of Use.
Chimerix | Antiviral Drugs | Pipeline and Technologies
http://www.chimerix.com/discovery-clinical-trials/pipeline
Research & Development. Financials & Fillings. Research & Development. For most people, common viruses aren’t major health challenges. But for immunocompromised individuals, certain viruses can pose major threats to their health. Our current focus at Chimerix is on developing safe and effective antivirals for the prevention of cytomegalovirus (CMV) and treatment of adenovirus in patient populations with weakened immune systems. Lipid Conjugate Technology Platform. A third conjugate, CMX669. Chimerix also...
Chimerix | Antiviral Drugs for DNA Viruses | About Us
http://www.chimerix.com/company
Research & Development. Financials & Fillings. At Chimerix, we’re dedicated to preventing. And treating life-threatening viral infections. We make commitments and live up to them. By empowering individuals to take ownership and harnessing the agility of our organization, we are able to deliver on our promises exceeding expectations of quality, value and timeliness. We are entrepreneurs who leverage both scientific ingenuity and business expertise to develop creative solutions that transform our industry.
Chimerix | Antiviral Drugs for DNA Viruses | Home
http://www.chimerix.com/healthcare-professionals
Research & Development. Financials & Fillings. The potential to protect and provide hope for immunocompromised patients. With a goal of supporting those whove been there all along. Working to potentially expand treatment options for healthcare professionals. Together we can potentially build a more hopeful world for immunocompromised patients. The Need for Antiviral Protection. Number of hematopoietic cell transplants (HCT) performed each year worldwide. Open-label trial designed to evaluate the safety a...
TOTAL LINKS TO THIS WEBSITE
33
Overview | Checkpoint Therapeutics
SEC Filings and Financials. SEC Filings and Financials. Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 A Novel Third-Generation EGFR Inhibitor. Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference. Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 A Novel Third Generation EGFR Inhibitor. Checkpoint Therapeutics, Inc. New York, NY 10014. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the ent...
ChemCollective
Online Resources for Teaching and Learning Chemistry. We've recently updated our site. If you are having problems, you can click here to get to the old site. Resources to Teach and Learn Chemistry. The ChemCollective is a collection of virtual labs. Qualitative and Quantitative Analysis of Food Dyes. Release of new HTML5 Virtual Lab. Kinetics of Bleaching of Food Dyes Activity. The ChemCollective site and its contents are licensed under a Creative Commons Attribution 3.0 NonCommercial-NoDerivs License.
Chemed Corporation | Investor Relations | Investor Relations Home
Q2 2015 Chemed Corporation Earnings Conference Call. 160;at 10:00 am ET. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation operates two wholly owned subsidiaries: VITAS Healthcare Corporation. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. Chemed Corporation Increases Quarterly Dividend. Chemed Reports Second-Quarter 2015 Results. 160; 1.04.
Overview | ChemoCentryx, Inc.
Skip to main navigation. Great Science. Great Medicine. Orphan and Rare Diseases. Immuno-Oncology and Other Therapeutic Areas. Other Inflammatory and Autoimmune Diseases. Th17 Driven Diseases and CCR6. Orphan and Rare Diseases. Other Inflammatory and Autoimmune Diseases. Orphan and Rare Diseases. Immuno-Oncology and Other Therapeutic Areas. Other Inflammatory and Autoimmune Diseases. Th17 Driven Diseases and CCR6. Orphan and Rare Diseases. Other Inflammatory and Autoimmune Diseases. View all news releases.
Chiasma
You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE. For the potential treatment of adults with acromegaly. Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017. Learn about Chiasma’s corporate mission and values.
Investor Overview - Chimerix, Inc.
Discovery and Clinical Trials. Annual Reports and Proxies. 4:00 P ET on 08/14/15. 097 (- 1.90%). Delayed at least 20 minutes. August 6, 2015. Chimerix Announces Second Quarter 2015 Financial Results. August 3, 2015. Chimerix Completes Targeted Enrollment for Brincidofovir Phase 3 AdVise Trial for Adenovirus Infection. July 30, 2015. Chimerix to Announce Second Quarter 2015 Financial Results on August 6, 2015. View all press releases ». August 6, 2015 at 8:30 AM ET.
Embassy of the People's Republic of China in the Islamic Republic of Iran
ChinaCache International Holdings Ltd. - Investor Relations
Rsaquo; Investor Relations. ABOUT US / OUR BUSINESS. ChinaCache is the leading total solutions provider of Internet content and application delivery services in China, including Internet data center operations and Internet exchange centers. We provide a portfolio of services and solutions to businesses, government agencies and other enterprises to enhance the reliability and scalability of their online services and applications and improve end-user experience. View all ». Feb 7, 2018. Dec 21, 2017.
域名售卖
China Cord Blood Corporation - Investor Relations -Investor Relations Home
About Cord Blood Banking. Clinical Benefits of Cord Blood Stem Cells. Cord Blood Bank FAQ. China Cord Blood Corporation. 06 Aug. 2015. China Cord Blood Corporation Announces Receipt of Non-Binding Acquisition Proposal. 31 Jul. 2015. China Cord Blood Corporation Files Its Annual Report on Form 20-F. 19 Jun. 2015. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2015. 09 Jun. 2015. Annual Report for Fiscal Year 2015 (20-F). 160; 0.28. 06 Aug. 2015. Data ...
ChinaEdu
Primary and Secondary Schools. Conduct, Ethics and Duties. ChinaEdu in the News. ChinaEdu Corporation Announces Structural Management Changes Including the Appoi. ChinaEdu Corporation to Announce Fourth Quarter 2011 Financial Results on March. ChinaEdu Corporation Appoints Ben Cheng as a Director. ChinaEdu Corporation to Announce First Quarter 2012 Financial Results on June 13. ChinaEdu Reports Fourth Quarter and Fiscal Year 2011 Results. ChinaEdu Corporation Files Its Annual Report on Form 20-F.
SOCIAL ENGAGEMENT